Telomerase as a therapeutic target. Therapeutic potential of telomerase inhibitors.
Double
John A
JA
Cancer Research Unit, University of Bradford, Bradford, West Yorkshire, UK.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006131:Growth Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D012313:RNA / Q000037:antagonists & inhibitors; D019098:Telomerase / Q000037:antagonists & inhibitors*; D016615:Telomere / Q000187:drug effects
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; D009363:Neoplasm Proteins; C422952:telomerase RNA; D012313:RNA; D019098:Telomerase